Trial Profile
A Phase 2, Single Arm Study of CG0070 Combined With Pembrolizumab in Patients With Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Jun 2023
Price :
$35
*
At a glance
- Drugs Cretostimogene grenadenorepvec (Primary) ; Pembrolizumab (Primary)
- Indications Bladder cancer; Carcinoma
- Focus Therapeutic Use
- Acronyms CORE-001; CORE1
- Sponsors CG Oncolgy
- 01 May 2023 Results assessing the effect of of Cg0070 Combined with Pembrolizumab in Patients with Non Muscle Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin presented at the 118th Annual Meeting of the American Urological Association
- 01 May 2023 According to a CG Oncolgy media release, the company plan to follow the patients in complete remission beyond 12 months to ascertain longer-term response to cretostimogene grenadenorepvec and pembrolizumab.
- 01 May 2023 According to a CG Oncolgy media release, results from this trial were presented in an oral presentation at the American Urological Association (AUA) 2023 Annual Meeting.